IPW
VERV

Impact Partnership Wealth’s Verve Therapeutics VERV Stock Holding History

Impact Partnership Wealth’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-12,466
Closed -$70.3K – 346
2024
Q4 		$70.3K Buy
+12,466
New +$70.3K 0.01% 287

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Impact Partnership Wealth's VERV Position: Q1 2025 in Review

Impact Partnership Wealth sold out of Verve Therapeutics (VERV) in Q1 2025, closing a stake of 12,466 shares — an estimated $70.3K sold.

Impact Partnership Wealth first reported a position in VERV in Q4 2024 and held it in 1 quarter. The position peaked at $70.3K in Q4 2024. 191 funds tracked by Wall St. Rank hold VERV as of Q1 2025.

  • Impact Partnership Wealth reported no remaining Verve Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Impact Partnership Wealth sold 12,466 Verve Therapeutics shares in Q1 2025, an estimated $70.3K.
  • Impact Partnership Wealth first reported a position in Verve Therapeutics in Q4 2024 and held it in 1 quarter.
  • Impact Partnership Wealth's Verve Therapeutics position peaked at $70.3K in Q4 2024.
  • 191 funds tracked by Wall St. Rank held Verve Therapeutics as of Q1 2025.

Based on Impact Partnership Wealth's 13F filing for Q1 2025, filed 5 May 2025.